Neoadjuvant ipilimumab plus nivolumab in locally advanced melanoma: A real-world single-centre retrospective study
Background: Neoadjuvant immune-checkpoint inhibition (neoICI) with ipilimumab and nivolumab has shown high pathologic response rates as well as a long-lasting relapse-free survival in stage III melanoma patients. However, safety and efficacy data from real-world patients is very limited. Methods: St...
Saved in:
| Main Authors: | Patrick Schummer, Valerie Glutsch, Lukas Haug, Mathias Rosenfeldt, Johann Lock, Michael Meir, Agmal Scherzad, Detlef Klein, Matthias Goebeler, Hermann Kneitz, Bastian Schilling, Anja Gesierich |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | EJC Skin Cancer |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611823000034 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01) -
Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma
by: Taylor C. Peak, et al.
Published: (2020-01-01) -
Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab
by: Adnan Kilani, et al.
Published: (2023-01-01) -
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
by: Tanja D de Gruijl, et al.
Published: (2024-09-01) -
Neoadjuvant immunotherapy with ipilimumab/nivolumab induces a complete response of a primary malignant melanoma in an 89 years old patient
by: Pascal Spahn, et al.
Published: (2024-12-01)